

# UC Irvine

## UC Irvine Previously Published Works

### Title

Microvascular Effects of Pulsed Dye Laser in Combination With Oxymetazoline.

### Permalink

<https://escholarship.org/uc/item/53m945zj>

### Journal

Lasers in surgery and medicine, 52(1)

### ISSN

0196-8092

### Authors

Kelly, Alexis  
Pai, Alexander  
Lertsakdadet, Ben  
et al.

### Publication Date

2020

### DOI

10.1002/lsm.23186

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Microvascular Effects of Pulsed Dye Laser in Combination With Oxymetazoline

Alexis Kelly,<sup>1</sup> Alexander Pai,<sup>1</sup> Ben Lertsakdadet, PhD,<sup>1</sup> Bernard Choi, PhD,<sup>1,2,3</sup> and Kristen M. Kelly, MD, <sup>1,4\*</sup>

<sup>1</sup>Beckman Laser Institute and Medical Clinic, University of California, 1002 Health Sciences Rd, Irvine, California, 92617

<sup>2</sup>Department of Biomedical Engineering, Henry Samueli School of Engineering, University of California, 3120 Natural Sciences II, Irvine, California, 92697-2715

<sup>3</sup>Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California, 2400 Engineering Hall, Irvine, California, 92697-2730

<sup>4</sup>Department of Dermatology, University of California, 118 Medical Surge, Irvine, California, 92697-2400

**Background and Objective:** Oxymetazoline, an  $\alpha$ -1A agonist, is approved by the United States Food and Drug Administration (FDA) for treatment of persistent facial erythema associated with rosacea and induces vasoconstriction by interacting with  $\alpha$  receptors. The objective of our study was to study the microvascular effects of oxymetazoline and pulsed dye laser (PDL).

**Materials and Methods:** A dorsal window chamber was surgically installed on 20 mice. Each animal was assigned to one of four experimental groups: saline alone, oxymetazoline alone (10  $\mu$ l applied once daily  $\times$  7 days), saline + PDL (saline applied 5 minutes before PDL irradiation [10 mm spot, 1.5 ms pulse duration, 7 J/cm<sup>2</sup> delivered to epidermis]), or oxymetazoline + PDL (10  $\mu$ l oxymetazoline applied 5 minutes before PDL and then once daily  $\times$  7 days). Brightfield and laser speckle imaging were performed for 7 days to monitor vascular architectural and functional changes.

**Results:** We observed persistent blood flow in all of the saline-only and oxymetazoline-only experiments. A higher rate of vascular shutdown was observed with oxymetazoline + PDL (66.7%) compared with saline + PDL alone (16.7%). Oxymetazoline application increased venule diameter at 5 minutes post-application and decreased both arteriole and venule diameters at 60 minutes post-application.

**Conclusion:** The combination protocol of oxymetazoline + PDL induces persistent vascular shutdown observed 7 days after irradiation. This result may be associated with the acute vascular effects of oxymetazoline. Oxymetazoline + PDL should be evaluated as a treatment for cutaneous vascular disease, including rosacea and port wine birthmarks. *Lasers Surg. Med.* © 2019 Wiley Periodicals, Inc.

**Key words:** oxymetazoline; dorsal skinfold; laser speckle contrast; phototherapy

## INTRODUCTION

Rosacea affects roughly 16 million Americans and can have significant psychosocial impacts on a patient's

quality of life [1]. There are multiple treatments, but many patients do not find significant relief from available options. Erythematotelangiectatic rosacea, which presents with vasodilation and telangiectasias, can be particularly challenging to treat [1]. Pulsed dye laser (PDL) treatment can be utilized, but many patients require multiple treatments, and recurrence is frequent.

Topical medications have also been utilized to treat rosacea. For instance,  $\alpha$  agonists induce vasoconstriction via interaction with  $\alpha$  receptors. Brimonidine is an  $\alpha$ -2 agonist that was approved for persistent facial erythema associated with rosacea in 2013. While efficacy of this medication was demonstrated, some patients stopped application due to adverse effects including worsening of facial erythema [2]. Oxymetazoline, an  $\alpha$ -1A agonist, was more recently approved by the United States Food and Drug Administration (FDA) for treatment of persistent facial erythema associated with rosacea. This medication appears to have an improved side effect profile [3,4].

Ryan et al. [5] evaluated two patients with persistent facial erythema for 7 hours after the application of oxymetazoline. With optical coherence tomography, they noted that at approximately 5 minutes after application, the vascular area was increased, followed by a subsequent decrease of the vascular area by 60 minutes and a return to baseline levels at 1–2 days post-treatment. Hence, oxymetazoline appears to induce acute vascular changes.

Combination treatments with laser and topical medication can provide an enhanced result, achieving a better effect than either treatment modality alone [6,7]. Here, we evaluate the preclinical potential of

**Abbreviations:** LSI, laser speckle imaging; PDL, pulsed dye laser.

Alexis Kelly and Alexander Pai share first authorship.

Bernard Choi and Kristen M. Kelly share senior authorship.

\*Correspondence to: Kristen M. Kelly, MD, Beckman Laser Institute and Medical Clinic, University of California, Irvine, 1002 Health Sciences Road East, Irvine, CA 92612. E-mail: kmkelly@uci.edu

Accepted 31 October 2019

Published online 22 November 2019 in Wiley Online Library (wileyonlinelibrary.com). Published online in Wiley Online Library (wileyonlinelibrary.com).

DOI 10.1002/lsm.23186

combined oxymetazoline and PDL for the treatment of cutaneous vascular disease, using a translational preclinical *in vivo* model of the microvasculature. We hypothesized that combining oxymetazoline with PDL would result in increased rates of persistent vascular shutdown, compared with saline with PDL.

## MATERIALS AND METHODS

### Animal Model

This study was approved by the Institutional Animal Care and Use Committee at University of California, Irvine. Twenty adult (20–25 g) C3H mice were used in this study. Figure 1 provides a timeline of procedures. For each experiment, a rodent dorsal window chamber was installed (Fig. 1a) [8]. Before the surgery, each mouse was anesthetized with isoflurane (2%, balance oxygen) followed by i.p. injection of a cocktail of ketamine (90 mg/kg) and xylazine (10 mg/kg). The dorsum was shaved and the remaining hair removed using a depilatory cream (Nair). The dorsal skin was pulled upwards, and two bio-compatible titanium plates were installed with screws and sutures on to each side of the skinfold. One ~10 mm diameter, full-thickness region of skin was removed with surgical scissors and excess fascia gently dissected from the subdermal side of the remaining full thickness of skin. Sterile saline was applied on to the subdermal side and a circular glass coverslip placed on top of the subdermal side to maintain hydration and mitigate the risk of infection. A metal retaining clip was placed on top of the coverslip to maintain its position. The body temperature was maintained using a heating pad and monitored throughout the procedure. After the window chamber surgery was completed, the animal was allowed to recover for 2 days.

### Wide-Field Optical Imaging

To monitor structural and functional changes to the microvasculature, we used a combination brightfield/laser speckle imaging (LSI) device described previously [9]. A scientific CCD camera (Chameleon; FLIR Systems, Wilsonville, OR) equipped with a macro lens (Nikon, Tokyo, Japan) was used for imaging. Each animal was positioned so that the subdermal side of the window chamber was proximal to the camera. For brightfield imaging, a white-light source equipped with a green filter was used to transilluminate the window chamber. The filter was used to maximize visualization of the microvasculature, using hemoglobin absorption as the primary source of contrast. For LSI, a 30-mW, 633 nm HeNe laser (Edmund Optics, Barrington, NJ) was used to transilluminate the window chamber. For all LSI images, the camera exposure time was set to 10 ms and a sequence of 30 images collected.

### Experimental Design

The animals were divided into four experimental groups: saline alone ( $n = 3$ ), oxymetazoline alone ( $n = 5$ ), saline + PDL ( $n = 6$ ), and oxymetazoline + PDL ( $n = 6$ ). On



**b**

Day	Procedure
-2	Dorsal window chamber surgery
0	Brightfield and laser speckle imaging
	Application of either oxymetazoline or saline
	Wait 5 min
	PDL (if applicable)
	Brightfield and laser speckle imaging (t = 5 min)
	Brightfield and laser speckle imaging (t = 60 min)
1-6	Application of either oxymetazoline or saline
7	Brightfield and laser speckle imaging




Fig. 1. Workflow of experiments. (a) Rodent dorsal window chamber model. (b) Chart listing the workflow for experiments. (c) Example of selection process for regions of interest. Asterisks denote selection of a venule region while  $\times$  denote selection of an arteriole region.

Day 0 (i.e., 2 days post-surgery), brightfield imaging and LSI was performed before the application of either oxymetazoline or saline. Ten microliters of oxymetazoline or saline was applied to the epidermal side of the window. The oxymetazoline or saline was applied to all experimental groups at approximately the same time each day for 7 days after the initial application. The mice

from the saline alone and oxymetazoline alone groups were imaged again at 5 minutes and 60 minutes post-application. For the saline + PDL and oxymetazoline + PDL groups, PDL irradiation (10 mm spot; 1.5 ms pulse duration;  $7 \text{ J/cm}^2$  radiant exposure) was applied to the epidermal side at 5 minutes post-application of oxymetazoline or saline, in accordance with a previously reported observation [5] of increased vascular volume at this time point. These mice were then imaged at 5 minutes and 60 minutes post PDL. LSI was repeated at 5 minutes post-application on Days 1, 2, 3, and 7; and 60 minutes post-application on Days 2 and 7 (Fig. 1b).

### Image Analysis

To determine changes in arteriole and venule diameter in response to oxymetazoline or saline application, we selected five regions of interest (Fig. 1c) within segments of arterioles and venules in the brightfield images. From these regions, vessel diameters were estimated. The same regions of interest were characterized at each subsequent time point. To determine changes in blood flow in response to oxymetazoline or saline application, we converted each raw speckle image of a given sequence into a speckle contrast image, using a  $7 \times 7$  sliding window, as previously described [10]. Each speckle contrast image was converted to a Speckle Flow Index (SFI) image, commonly used as a map of blood flow. A mean SFI image was calculated from each SFI image in the sequence. The same regions of interest selected in a corresponding brightfield image were applied to the mean SFI images to calculate a single SFI image of each region of interest. Statistical analysis included parametric (paired  $t$  test) and non-parametric tests (Wilcoxon's matched-pairs signed-rank test) performed in Prism (Version 8; GraphPad Software, San Diego, CA) to test the null hypotheses that there is no change in vessel diameter or blood flow with oxymetazoline application.

### RESULTS

We observed persistent blood flow in all of the saline alone ( $n = 3$ ) and oxymetazoline alone ( $n = 5$ ) experiments (Fig. 2a). Most (5/6) of the saline + PDL experiments resulted in a significant decrease in perfusion 5 minutes post PDL on Day 0. On Day 7, 5/6 experiments exhibited at least partial reperfusion of the window chamber (Fig. 2b). In contrast, 4/6 of the oxymetazoline + PDL experiments had persistent vascular shutdown (Fig. 2c), 1/6 had reperfusion on Day 7, and 1/6 exhibited substantial vascular remodeling (Fig. 2d), with smaller, tortuous vessels indicative of angiogenesis. These data collectively suggest that persistent vascular shutdown can be achieved with a combined oxymetazoline + PDL treatment protocol.

To elucidate the mechanism of the differences in shutdown rates seen in the various treatment groups, we analyzed changes in vessel diameter and blood flow. Venule diameter increased ( $P = 0.03$ ) at 5 minutes post-application of oxymetazoline and was smaller ( $P = 0.002$ ) at




Fig. 2. Representative images of changes in vasculature after 7 days. The top (colored) panels are Speckle Flow Index Maps, and the bottom (greyscale) panels are Brightfield Images. (a) Application of only oxymetazoline showed no signs of vascular shutdown. (b) Pulsed dye laser (PDL) with saline showed immediate shutdown after initial treatment, but exhibited reperfusion after the 7-day observation period. (c) PDL with oxymetazoline resulted in persistent vascular shutdown over the 7 days. (d) One of the six PDL with oxymetazoline experiments displayed remodeling of vasculature with tortuous vessels.

60 minutes post-application (Fig. 3). At 5 minutes post-application, arteriole diameter was unchanged at 5 minutes (Fig. 3), but arteriole flow was higher ( $P = 0.04$ ) (Fig. 4). Arteriole diameter also was smaller ( $P = 0.02$ ) at 60 minutes post-application (Fig. 3). Both arteriole




Fig. 3. Acute effect of oxymetazoline on vessel diameter. (a) Immediate ( $t = 5$  min) effect of oxymetazoline on (left) venule and (right) arteriole diameter. Diameters of vessels (five vessels/animal) identified with transillumination green-light imaging. There is a significant increase in venule diameter ( $P = 0.032$ ,  $n = 5$ ) but no change in arteriole diameter ( $P = 0.98$ ,  $n = 5$ ). (b) Short-term ( $t = 60$  min) effect of oxymetazoline on (left) venule and (right) arteriole diameter. There is a significant decrease in venule diameter ( $P = 0.018$ ,  $n = 5$ ) and arteriole diameter ( $P = 0.016$ ,  $n = 5$ ). The solid line in each graph represents no change in vessel diameter.

diameter ( $P = 0.0001$ ) and blood flow ( $P = 0.03$ ) were increased at Day 7 (Fig. 5).

## DISCUSSION

Our data suggest that the oxymetazoline + PDL protocol resulted in more consistent vascular shutdown than any of the other study groups. Saline + PDL did result in an initial decrease in flow, but reperfusion occurred over the 7-day observation period; this result is in agreement with our previous findings using similar PDL settings. As expected, saline alone and oxymetazoline alone did not result in vascular shutdown.

Oxymetazoline alone did affect the vasculature. After oxymetazoline application, we observed an increase in venule diameter at 5 minutes post-application (but no change in arteriole diameter) and a decrease in both arteriole and venule diameters at 60 minutes post-application. These trends are in agreement with optical coherence tomography measurements of blood volume in human subjects receiving topical oxymetazoline [5]. Previous research reported that different subtypes of  $\alpha 1$  receptors vary in their effects on arterioles versus venules.  $\alpha 1A$  receptors, which are targeted by  $\alpha 1A$  agonists such as oxymetazoline, play a more critical role in the maintenance of blood pressure in arterioles than in

venules [11]. This observation suggests that we would have observed a more significant effect on arterioles than on venules. However, results from other studies indicate that while oxymetazoline has a high affinity to  $\alpha 1A$  receptors, it has a lower affinity to  $\alpha 2B$  receptors, which are primarily involved in the contraction of arterioles [12,13]. Also, the constriction response in venules is mediated primarily by  $\alpha 1B$  and  $\alpha 2D$  adrenergic receptors [12]. Ligands often recognize more than one adrenoceptor subtype, which may explain the effect that oxymetazoline alone had on both venules and arterioles [11]. The effects of oxymetazoline need to be further investigated to understand better the mechanisms associated with the persistent vascular shutdown that we observed in the oxymetazoline + PDL group.

Our data do not fully explain the improved shutdown observed with combined oxymetazoline + PDL. However, we did observe an increased venule diameter at 5 minutes and decrease at 60 minutes, which together likely contributed to the observed effect. An increase in vessel diameter would increase the local volume of hemoglobin, which in turn would increase the volumetric heat generation resulting from PDL irradiation. The decrease in arteriole and venule diameter at 60 min may facilitate the ensuing photo-induced coagulation effect [14]. This demonstration of persistent vascular shutdown with oxy-




Fig. 4. Acute effect of oxymetazoline on blood flow. (a) Immediate ( $t=5$  min) effect of oxymetazoline on (left) venule and (right) arteriole blood flow. Speckle Flow Index of vessels (five vessels/animal) identified with transillumination green-light imaging. There is a significant increase in arteriole blood flow ( $P=0.039$ ,  $n=5$ ) but no change in venule blood flow ( $P=0.55$ ,  $n=5$ ). (b) Short-term ( $t=60$  min) effect of oxymetazoline on (left) venule and (right) arteriole blood flow. There is no significant change in venule ( $P=0.11$ ,  $n=5$ ) or arteriole blood flow ( $P=0.43$ ,  $n=5$ ). The solid line in each graph represents no change in vessel diameter.




Fig. 5. Longer-term (7-day) effect of oxymetazoline on (a) vessel diameter and (b) blood flow. (a) Vessel diameter of vessels (five vessels/animal) identified with transillumination green-light imaging. There is no change in venule diameter ( $P=0.11$ ,  $n=4$ ) but a significant increase in arteriole diameter ( $P<0.0001$ ,  $n=4$ ). (b) One week change in blood flow. There is no significant change in venule blood flow ( $P=0.75$ ,  $n=4$ ). A significant increase in arteriole blood flow ( $P=0.027$ ,  $n=4$ ) was observed. The solid line in (a) represents no change in vessel diameter, and in (b) represents no change in vessel blood flow.

metazoline + PDL suggests that this combination protocol may offer improved results for the treatment of cutaneous vascular disease, including rosacea and vascular malformations such as port wine birthmarks. Clinical trials are required to determine the safety and efficacy of the combination treatment for these indications.

Limitations exist in our study. Despite the statistically significant results and trends identified in this study, the power of these findings is limited due to a small sample size. Also, the skin and vasculature of the mouse dorsal window chamber differ from humans. Although the pre-clinical model serves as a common model for translational studies of phototherapies [15,16], the parameters used here may differ from those with therapeutic efficacy on human subjects. We would expect that the increased flow at 5 minutes followed by vasoconstriction that we observed, would occur in humans as well, but this will need to be confirmed in clinical studies.

## CONCLUSIONS

The combination protocol of oxymetazoline + PDL induces persistent vascular shutdown observed 7 days after irradiation. This result may be associated with the acute vascular effects of oxymetazoline, including a pre-PDL increase in venule diameter followed by vasoconstriction observed in arterioles and venules at 60 minutes post PDL. Oxymetazoline + PDL should be evaluated as a treatment for cutaneous vascular disease, including rosacea and port wine birthmarks.

## ACKNOWLEDGMENTS

This work was generously supported by a research grant from Allergan. We acknowledge support from the Arnold and Mabel Beckman Foundation, the NIH Laser Microbeam, and Medical Program Grant P41 EB015890, and the NIH funded Institute of Clinical and Translational Science TL1 TR001415 Fellowship to Ben Lertsakdatet. We gratefully acknowledge the work of Sean White on Figure 1.

## ORCID

Kristen M. Kelly  <http://orcid.org/0000-0002-5988-2197>

## REFERENCES

1. Zeichner JA, Eichenfield LF, Feldman SR, Kasteler JS, Ferrusi IL. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea. *J Clin Dermatol* 2018;11(2):47–52.
2. Del Rosso JQ. Topical  $\alpha$ -agonist therapy for persistent facial erythema of rosacea and the addition of oxymetazoline to the treatment. *J Clin Aesthet Dermatol* 2017 Jul;10(7):28–32. Epub 2017 Jul 1.
3. Patel NU, Shukla S, Zaki J, Feldman SR. Oxymetazoline hydrochloride cream for facial erythema associated with Rosacea. *Expert Rev Clin Pharmacol* 2017;10(10):1049–1054.
4. Stein-Gold L, Kircik L, Draelos AD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: Pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. *J Drugs Dermatol* 2018;17(1):1201–1208.
5. Ryan H, Graham PM, Woods D, McDaniel DH. Optical coherence tomography evaluation of topical oxymetazoline hydrochloride treatment efficacy for rosacea. *Lasers Surg Med* 2018;50:S39.
6. Lipner S. Topical adjuncts to pulsed dye laser for treatment of port wine stains: Review of the literature. *Dermatol Surg* 2018;44(6):796–802.
7. Bae-Harboe Y, Geronemus R. Targeted topical and combination laser surgery for the treatment of angiofibromas. *Lasers Surg Med* 2013;45(9):555–557.
8. Moy AJ, White SM, Indrawan ES, et al. Wide-field functional imaging of blood flow and hemoglobin oxygen saturation in the rodent dorsal window chamber. *Microvascular research* 2011;82(3):199–209.
9. Jia W, Tran N, Sun V, et al. Photocoagulation of dermal blood vessels with multiple laser pulses in an in vivo microvascular model. *Lasers Surg Med* 2012;44:144–151.
10. Boas DA, Dunn AK. Laser speckle contrast imaging in biomedical optics. *J Biomed Opt* 2010;15:011109.
11. Civantos Calzada B, Aleixandre de Artiñano A. Alpha-adrenoceptor subtypes. *Pharmacol Res* 2001;44(3):195–208.
12. Leech CJ, Faber JE. Different alpha-adrenoceptor subtypes mediate constriction of arterioles and venules. *Am J Physiol* 1996;270(2 Pt 2):H710–H722.
13. Haenisch B, Walstab J, Herberhold S, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. *Fundam Clin Pharmacol* 2010;24(6):729–739.
14. Aguilar G, Choi B, Broekgaarden M, et al. An overview of three promising mechanical, optical, and biochemical engineering approaches to improve selective photothermolysis of refractory port wine stains. *Ann Biomed Eng* 2012;40:486–506.
15. Jia W, Sun V, Tran N, et al. Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: Implications for effective port wine stain treatment. *Lasers Surg Med* 2010;42(2):105–112.
16. Kelly KM, Moy WJ, Moy AJ, et al. Talaporfin sodium-mediated photodynamic therapy alone and in combination with pulsed dye laser on cutaneous vasculature. *J Invest Dermatol* 2015;135(1):302.